Tartrate-Resistant Acid Phosphatase
ACP5proteinTRAP reflects osteoclast activity and systemic bone metabolism but is not a direct atherothrombotic cascade mediator.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleBone-resorption marker; off atherothrombotic cascade.
Also acts inCap degradation / rupture, Vascular inflammation
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I39
C — confounder / Type-II70
A — assay feasibility68
E — evidence strength26
T1DI (composite)6
Specificity differential (R−C)-31
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes.Journal of thrombosis and thrombolysis · 2021 · PMID 34708315 · doi
- Lysophospholipids as Predictive Markers of ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).Metabolites · 2020 · PMID 33396480 · doi